WO2010151495A3 - Materials and methods for treating and preventing viral infections - Google Patents

Materials and methods for treating and preventing viral infections Download PDF

Info

Publication number
WO2010151495A3
WO2010151495A3 PCT/US2010/039195 US2010039195W WO2010151495A3 WO 2010151495 A3 WO2010151495 A3 WO 2010151495A3 US 2010039195 W US2010039195 W US 2010039195W WO 2010151495 A3 WO2010151495 A3 WO 2010151495A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
animal
viral infection
peptide
virus
Prior art date
Application number
PCT/US2010/039195
Other languages
French (fr)
Other versions
WO2010151495A2 (en
Inventor
Howard M. Johnson
Chulbul Iqbal M. Ahmed
Original Assignee
University Of Florida Research Foundation Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Florida Research Foundation Inc. filed Critical University Of Florida Research Foundation Inc.
Publication of WO2010151495A2 publication Critical patent/WO2010151495A2/en
Publication of WO2010151495A3 publication Critical patent/WO2010151495A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The subject invention concerns materials and methods for inhibiting activity of a broad spectrum of viruses in humans and animals. In one embodiment of the invention, a method is provided for treating or preventing viral infection in an animal by administering an effective amount of peptide that is an antagonist of SOCS-I and/or SOCS-3. In a specific embodiment, the peptide corresponds to the activation loop of janus kinase JAK2. In an exemplified embodiment, the peptide has the amino acid sequence: LPQDKEYYKVKEP (pJAK2 (1001-1013)) (SEQ ID NO:1). Compositions contemplated within the scope of the invention include peptides of the invention and optionally one or more other antiviral compounds. Examples of viruses whose replication can be inhibited using the present invention include, but are not limited to, vaccinia virus, EMC virus, influenza virus, and herpes simplex virus. In addition to treating a human or animal having a viral infection, the subject invention can also be used to prevent viral infection in an uninfected human or animal.
PCT/US2010/039195 2009-06-26 2010-06-18 Materials and methods for treating and preventing viral infections WO2010151495A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22092009P 2009-06-26 2009-06-26
US61/220,920 2009-06-26
US35412410P 2010-06-11 2010-06-11
US61/354,124 2010-06-11

Publications (2)

Publication Number Publication Date
WO2010151495A2 WO2010151495A2 (en) 2010-12-29
WO2010151495A3 true WO2010151495A3 (en) 2011-04-28

Family

ID=43387105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/039195 WO2010151495A2 (en) 2009-06-26 2010-06-18 Materials and methods for treating and preventing viral infections

Country Status (1)

Country Link
WO (1) WO2010151495A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343081A1 (en) * 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
GB201012651D0 (en) * 2010-07-28 2010-09-15 Univ Edinburgh Peptides
WO2012177892A2 (en) * 2011-06-21 2012-12-27 University Of Florida Research Foundation, Inc. Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis
CN102964432B (en) * 2012-11-22 2014-02-05 中国科学院微生物研究所 Method for restraining phosphorylation of M1 protein of influenza virus A and applications of method
CN103007350A (en) * 2012-12-14 2013-04-03 中国人民解放军第三军医大学第二附属医院 Modified rat accellular spinal cord bracket material and preparation method thereof
CN103266086B (en) * 2013-06-15 2014-11-19 中国人民解放军第一七四医院 Method for preparing dendritic cells for effectively submitting gastric cancer antigens
EP3096775B1 (en) * 2014-01-24 2023-01-11 University of Florida Research Foundation, Inc. Socs mimetics for the treatment of diseases
ES2552587B1 (en) 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca PEPTIDE DERIVED FROM SOCS1 FOR USE IN CHRONIC COMPLICATIONS OF THE DIABETES
CN110183515B (en) * 2019-04-28 2020-09-29 浙江中医药大学 Polypeptide for PTP1B detection and fluorescent probe containing polypeptide
KR102588548B1 (en) * 2019-07-16 2023-10-16 주식회사 젠센 Peptide Therapeutic Agent of Autoimmune Diseases and Inflammatory Diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142466A1 (en) * 1999-04-20 2002-10-03 Flier Jeffrey S. Methods and compositions for modulating ciliary neurotrophic factor activity
US6683052B1 (en) * 1998-02-06 2004-01-27 Institut National De La Sante Et De La Recherche Medicale Inserm Lipopeptides containing an interferon-γ fragment, and uses thereof in pharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683052B1 (en) * 1998-02-06 2004-01-27 Institut National De La Sante Et De La Recherche Medicale Inserm Lipopeptides containing an interferon-γ fragment, and uses thereof in pharmaceutical compositions
US20020142466A1 (en) * 1999-04-20 2002-10-03 Flier Jeffrey S. Methods and compositions for modulating ciliary neurotrophic factor activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AHMED, C. M. ET AL.: "Enhancement of antiviral immunity by small molecule antagonist of suppressor of cytokine signaling.", J. IMMUNOL., vol. 185, no. 2, 11 June 2010 (2010-06-11), pages 1103 - 1113, XP002634872, DOI: doi:10.4049/JIMMUNOL.0902895 *
FREY, K. G. ET AL.: "HSV-1-induced SOCS-1 expression in keratinocytes: use of a SOCS-1 antagonist to block a novel mechanism of viral immune evasion.", J. IMMUNOL., vol. 183, no. 2, 19 June 2009 (2009-06-19), pages 1253 - 1262, XP055148620, DOI: doi:10.4049/jimmunol.0900570 *
MULLINS, D. W. ET AL.: "Taxol, a microtubule-stabilizing antineoplastic agent, differentially regulates normal and tumor-bearing host macrophage nitric oxide production.", IMMUNOPHARMACOLOGY., vol. 37, no. 1, August 1997 (1997-08-01), pages 63 - 73 *
WAIBOCI, L. W. ET AL.: "Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist.", J. IMMUNOL., vol. 178, no. 8, 15 April 2007 (2007-04-15), pages 5058 - 5068, XP055065414 *

Also Published As

Publication number Publication date
WO2010151495A2 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
WO2010151495A3 (en) Materials and methods for treating and preventing viral infections
PH12018550201A1 (en) Hepatitis b antiviral agents
ZA202002139B (en) Combination pharmaceutical agents as rsv inhibitors
WO2019143902A3 (en) Substituted heterocycles as antiviral agents
WO2012065963A3 (en) Antiviral condensed heterocyclic compounds
WO2007038507A3 (en) Modified 4'-nucleosides as antiviral agents
WO2009091388A3 (en) Triazines and related compounds having antiviral activity, compositions and methods thereof
TW200732351A (en) New cyclic peptide compounds
BR112012033117A2 (en) pyrazolo [1,5-a] pyrimidines as antiviral agents
EP2580209A4 (en) Inhibitors of hcv ns5a protein
MX2020002191A (en) Hepatitis b antiviral agents.
NZ607477A (en) Non-natural amino acid replication-dependent microorganisms and vaccines
MX2009011512A (en) New cyclic peptide compounds.
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
MX2022009352A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus.
WO2005007078A3 (en) Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars)
WO2010101649A3 (en) Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
WO2007084435A8 (en) Methods for treating hepatitis c
WO2009094190A3 (en) Methods of treating viral infections
CA2862755A1 (en) Antiviral compounds with a dibenzooxaheterocycle moiety
PH12021550979A1 (en) Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2- carboxamides active against the hepatitis b virus (hbv)
CA2399172A1 (en) Cold-adapted equine influenza viruses
EA201491969A1 (en) IMMUNOGENIC COMPOUNDS INCLUDING HIV PEPTIDE GP41, ASSOCIATED WITH CRM197 CARRIER MEDICINE
JP2015517484A5 (en)
WO2009120339A3 (en) Vectors for delivering disease neutralizing agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10792548

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 10792548

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE